erlotinib [Tarceva]
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Apr 1, 2009 → Nov 1, 2009
NCT ID
NCT01066884About erlotinib [Tarceva]
erlotinib [Tarceva] is a approved stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01066884. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (2) Terminated (2) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01609543 | Approved | Completed |
| NCT01372384 | Phase 2 | Completed |
| NCT01287754 | Approved | Completed |
| NCT01174563 | Phase 2 | Completed |
| NCT01250119 | Phase 2 | Completed |
| NCT01183858 | Phase 3 | Completed |
| NCT01066884 | Approved | Completed |
| NCT02013206 | Phase 2 | Completed |
| NCT01996332 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer